The FDA opted to handle quietly its findings on the potentially serious health threat tied to allegations that Cetero Research, a company that performed research for drugmakers worldwide, tampered with test data and manipulated records, write Rob Garver and Charles Seife. The FDA allowed certain treatments to remain on the market although it holds no additional scientific data to support their efficacy and safety. "They could have done more," former FDA investigator Patrick Stone said. "They should have done more."
Published in Brief: